Xalkori 200 MG capsule 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FG3PC
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,197
Award facts
- Contract value 100% obligated
- $16,196.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,196.75 to AmerisourceBergen Drug Corp for the supply of Xalkori (crizotinib) 200 mg capsules in a quantity of 60 units. This competitive, firm fixed-price delivery order was executed on January 20, 2026, with an ultimate completion date of February 10, 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a significant indefinite delivery contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the primary vehicle for supplying pharmaceutical products and medical supplies to military healthcare programs globally.
Xalkori is an oncology medication used in the treatment of non-small cell lung cancer, reflecting the Defense Logistics Agency's continued procurement of specialized pharmaceutical products to support military treatment facilities and veterans' healthcare systems. As a non-set-aside award, this delivery order was competitively awarded, demonstrating AmerisourceBergen's capability to meet federal procurement requirements for critical pharmaceutical commodities. The award aligns with the broader strategic mission of DLA's medical supply chain to maintain adequate inventory of essential medications across multiple therapeutic domains to support the Defense Health Agency and other federal healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FG3PC?
SPE2DR26FG3PC was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FG3PC worth?
The government has obligated $16,197 on SPE2DR26FG3PC.
Is contract SPE2DR26FG3PC an order under another contract?
Yes. SPE2DR26FG3PC is a delivery order under SPE2DR25D3016, an indefinite delivery contract.
Was contract SPE2DR26FG3PC competed?
The extent of competition for SPE2DR26FG3PC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award